- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04126707
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
September 7, 2021 updated by: Ascentage Pharma Group Inc.
A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C] HQP1351 After a Single Oral 30mg (100µCi) Dose in Healthy Chinese Male Subjects
The objective of this study is to determine the mass balance and routes of excretion of total radioactivity after a single oral 30mg (100µCi) dose of [14C] HQP1351 given as a suspension.
For further clinical development, human mass balance data are required to elucidate the absorption, metabolism, and excretion of HQP1351.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nanjing, China
- The First Affiliated Hospital with Nanjing Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
A subject will be eligible for study participation if he meets the following criteria:
- Healthy male volunteers between the ages of 18 to 50 years old, inclusive;
- Body weight >=50 kg, Body mass index (body weight(kg)/hight2(m2)) between 19 and 26 kg/m2 (inclusive);
- Normal physical findings, clinical laboratory values, vital signs and 12-lead ECG, or any abnormality that is non-clinically significant;
- Male subjects of reproductive potential with partners will be instructed to, and must be willing to practice a highly effective method of birth control for the duration of the study and continuing 1 year after discontinuing treatment with the investigational product.
- Must understand, and voluntarily sign the informed consent, comply with the requirements of the study.
Exclusion Criteria:
A subject will not be eligible for study participation if he meets any of the exclusion criteria:
- History of or current clinically significant cardio, pulmonary, endocrine, metabolism, renal, hepatic, gastrointestinal, dermatology, infection, hematology, neurological, mental disease or disorder;
- Positive test for HBsAg, HBeAg, anti-HCV, anti-HIV or syphilis antibody;
- Abnormality in blood pressure, including hypertensive BP (SBP>=140 mmHg, or DBP >=90 mmHg), or hypotensive BP (SBP<90 mmHg, or DBP <=55 mmHg), Pulse rate<55 bpm or >100 bpm;
- Long-QT syndrome or family history of it, or QTcB interval > 450 ms; intraventricular blocks or left/right bundle branch block or QRS>120ms; frequent ventricular ectopic beats (any 10s ECG ventricular premature beat >= 1 in screening period); or abnormal resting heart rate (> 100 bpm)
The following abnormal clinical laboratory values
- HGB < LLN or HGB>ULN, and is judged as clinically significant by the investigator;
- Abnormal ALB, TP, CRE, ALT, AST, BIL, BUN, GLU value, and is judged as clinically significant by the investigator;
- Received any drug within 14 days before taking the investigational drug, including any prescription drug, OTC drug, herbal drug or health care product with medicinal effect;
- Received any other investigating products or participated in any clinical trails three month before screening or within 10 t1/2 after receiving other investigating products;
- History of or current swallowing disorder, active gastrointestinal diseases, or other diseases that significantly affect absorption, distribution, metabolism and excretion of drugs;
- Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease or history of gastrointestinal surgery and cholecystectomy;
- Hemorrhoids or perianal disease with regular/perianal bleeding;
- Allergies, have allergies to two or more drugs or foods; or have known allergies to the components of the drug (microcrystalline cellulose, stearic acid, croscarmellose sodium);
- Have donated 400ml or more of blood or plasma 3 months prior to the study drug administration, or more than 50ml within 2 weeks prior to administration;
- Vaccination was administered within 6 months prior to screening or during screening;
- History of drug or alcohol abuse;
- Smoking (> 10 cigarette / day), drinking (> 15 g, pure alcohol / day, equivalent to 450 ml beer, 150 ml wine or 50 ml low-alcohol liquor), or abusing drugs within last 3 months;
- Subject with mentally ill and could not understand the property, scope and possible consequences of the study;
- subject in prison or whose freedom is restricted by administrative or legal issues;
- Failure to comply with clinical study protocols, such as non-cooperation, follow-up visit and completion of entire study;
- Abnormal coagulation function or known severe bleeding tendency;
- Subjects who have participated in radiolabeled clinical study prior to drug administration;
- Significant radiation exposure within one year prior to drug administration (more than one exposure from chest X-ray, CT scan, or barium meal examination and radiation-related occupations).
- Investigators think that subjects are not suitable to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C] HQP1351
To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (30mg, 100µCi) of [14C] HQP1351 to healthy Chinese male subjects.
|
Orally, single dose of 30mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radioactivity concentration of each blood and plasma sample
Time Frame: Day 1- Day 15
|
Use liquid scintillation counter to evaluate Radioactivity concentration of each blood and plasma sample
|
Day 1- Day 15
|
Radioactivity concentration of each urine samples
Time Frame: Day 1- Day 15
|
Use liquid scintillation counter to evaluate Radioactivity concentration of each urine sample
|
Day 1- Day 15
|
Radioactivity concentration of each feces samples
Time Frame: Day 1- Day 15
|
Use liquid scintillation counter to evaluate Radioactivity concentration of each feces sample
|
Day 1- Day 15
|
Total recovery of radioactivity in urine and feces
Time Frame: Day 1- Day 15
|
Calculate the total radioactivity in urine and feces based on the radioactivity concentration of each sample
|
Day 1- Day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma drug concentrations
Time Frame: Day 1- Day 15
|
To determine the plasma concentrations of HQP1351 with validated LC-MS/MS method for obtaining its pharmacokinetics parameters
|
Day 1- Day 15
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: Day 1- Day 15
|
According to CTCAE v5.0, the number and frequency of adverse events after a single dose of test drug were assessed.
|
Day 1- Day 15
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Feng Shao, Doctor, The First Affiliated Hospital with Nanjing Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 19, 2019
Primary Completion (Actual)
January 13, 2020
Study Completion (Actual)
January 13, 2020
Study Registration Dates
First Submitted
October 11, 2019
First Submitted That Met QC Criteria
October 11, 2019
First Posted (Actual)
October 15, 2019
Study Record Updates
Last Update Posted (Actual)
September 8, 2021
Last Update Submitted That Met QC Criteria
September 7, 2021
Last Verified
July 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HQP1351XC105
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myeloid Leukemia (CML)
-
UNC Lineberger Comprehensive Cancer CenterCompletedChronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous LeukemiaUnited States
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.RecruitingCML, Chronic Phase | CML, Accelerated PhaseChina
-
Il-Yang Pharm. Co., Ltd.RecruitingChronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML, Refractory | CML - Philadelphia ChromosomeTurkey, Korea, Republic of, Russian Federation, Ukraine
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)United States
-
Associazione Italiana Pazienti Leucemia Mieloide...Not yet recruitingChronic Myeloid Leukemia (CML)Italy
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Not yet recruiting
-
University of JenaNovartis Pharmaceuticals; Ludwig-Maximilians - University of MunichActive, not recruiting
-
Hybrigenics CorporationUnknown
-
University Hospital, AngersActive, not recruitingChronic Myeloid Leukemia (CML)France
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
Clinical Trials on [14C] HQP1351
-
xunaNanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital... and other collaboratorsWithdrawnProphylactic HQP1351 Therapy | Third Generation TKIChina
-
Ascentage Pharma Group Inc.HealthQuest Pharma Inc.RecruitingSolid Tumor, Adult | Gastrointestinal Stromal Tumor (GIST)China
-
Ascentage Pharma Group Inc.Active, not recruitingChronic Myeloid Leukemia, Chronic PhaseChina
-
Ascentage Pharma Group Inc.Active, not recruitingChronic Myeloid Leukemia - Accelerated PhaseChina
-
Ascentage Pharma Group Inc.HealthQuest Pharma Inc.CompletedChronic Myeloid Leukemia, Chronic PhaseChina
-
Shenzhen Second People's HospitalRecruitingChronic Myeloid Leukemia, Chronic Phase | Olverembatinib | Tyrosine Kinase InhibitorsChina
-
Indivior Inc.CompletedOpioid Use DisorderUnited States
-
Arcus Biosciences, Inc.Gilead SciencesCompleted
-
BiogenDenali Therapeutics Inc.Completed
-
Athira PharmaAlturas Analytics, Inc.; Labcorp Drug Development IncCompletedHealthy VolunteersUnited States